All Stories

  1. Deucravacitinib in Hidradenitis Suppurativa: An Open Label Proof of Concept Study

    Article • Journal of the American Academy of Dermatology, September 2026, Elsevier

    Dr John W Frew

  2. Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study

    Article • Journal of the European Academy of Dermatology and Venereology, July 2026, Wiley

    Dr John W Frew, Professor Gregor B Jemec

  3. Pyoderma Gangrenosum: A Retrospective Cohort Study of Comorbidities and Therapies in Over 65,000 Patients in the TriNetX Database

    Article • JEADV Clinical Practice, April 2026, Wiley

    Dr John W Frew

  4. Efficacy of Biologics for Hidradenitis Suppurativa: A Network Meta Analysis and Meta Regression for Baseline Disease Severity

    Article • Australasian Journal of Dermatology, March 2026, Wiley

    Dr John W Frew

  5. Predictors of Survival and Length of Stay in Steven Johnson syndrome and toxic epidermal necrolysis: A single centre retrospective study of 111 patients

    Article • Journal of Burn Care & Research, March 2026, Oxford University Press (OUP)

    Dr John W Frew

  6. Real‐World Efficacy and Drug Survival of Adalimumab in Australian Patients With Psoriasis

    Article • Australasian Journal of Dermatology, February 2026, Wiley

    Dr John W Frew

  7. Psychological Complications of Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta‐Analysis

    Article • Australasian Journal of Dermatology, October 2025, Wiley

    Dr John W Frew

  8. Time to Recognise Psoriasis as a Cardiovascular Risk Modifier in National Guidance

    Article • Australasian Journal of Dermatology, August 2025, Wiley

    Dr John W Frew

  9. Prevalence and predictors of posttraumatic stress disorder in Stevens Johnson syndrome and toxic epidermal necrolysis

    Article • Journal of the European Academy of Dermatology and Venereology, July 2025, Wiley

    Dr John W Frew

  10. The effects of isotretinoin on serum thyroid parameters: A systematic review and meta-analysis

    Article • June 2025, International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)

    Dr John W Frew

  11. Sequencing of Biologic Therapy in Hidradenitis Suppurativa: A Real‐World Analysis of Treatment in Over 15,000 Patients

    Article • JEADV Clinical Practice, June 2025, Wiley

    Dr John W Frew

  12. Unravelling the complex pathogenesis of hidradenitis suppurativa

    Article • British Journal of Dermatology, February 2025, Oxford University Press (OUP)

    Dr John W Frew

  13. Malignancy Risk Differs Between Hidradenitis Suppurativa and Pilonidal Sinus Disease:

    Article • Journal of the American Academy of Dermatology, February 2025, Elsevier

    Dr John W Frew

  14. Quantifying time to medical and/or surgical therapy after diagnosis of hidradenitis suppurativa and pilonidal sinus disease: A propensity‐matched real‐world cohort analysis

    Article • Journal of the European Academy of Dermatology and Venereology, December 2024, Wiley

    Dr John W Frew

  15. Intrinsic factors in the pathogenesis of hidradenitis suppurativa: Genetics, hormones, and the microbiome

    Article • Journal of the American Academy of Dermatology, December 2024, Elsevier

    Dr John W Frew

  16. Australasian hidradenitis suppurativa management guidelines

    Article • Australasian Journal of Dermatology, November 2024, Wiley

    Dr John W Frew

  17. The Clinical and Molecular Response of Pyoderma Gangrenosum to IL-23 Blockade: Result from a Proof-of-Concept Open-Label Clinical Trial

    Article • Journal of Investigative Dermatology, November 2024, Elsevier

    Dr John W Frew

  18. Systematic review and meta‐analysis of non‐SCORTEN predictors of mortality in Stevens‐Johnson syndrome and toxic epidermal necrolysis

    Article • International Journal of Dermatology, October 2024, Wiley

    Dr John W Frew

  19. Infectious complications of Stevens‐Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta‐analysis

    Article • International Journal of Dermatology, October 2024, Wiley

    Dr John W Frew

  20. A systematic review of case–control studies of cytokines in blister fluid and skin tissue of patients with Stevens Johnson syndrome and toxic epidermal necrolysis

    Article • Australasian Journal of Dermatology, June 2024, Wiley

    Dr John W Frew

  21. Tissue comparability and bias in hidradenitis suppurativa transcriptomic studies

    Article • Proceedings of the National Academy of Sciences, May 2024, Proceedings of the National Academy of Sciences

    Dr John W Frew

  22. A systematic review and meta-analysis of Non-SCORTEN mortality predictors in Stevens Johnson syndrome and toxic epidermal necrolysis

    Article • April 2024, International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)

    Dr John W Frew

  23. A systematic review and meta-analysis of case-control studies on cytokines in blister fluid and skin of patients with Stevens Johnson syndrome and toxic epidermal necrolysis

    Article • February 2024, International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)

    Dr John W Frew

  24. Infectious complications of Stevens Johnson syndrome and toxic epidermal necrolysis

    Article • January 2024, International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)

    Dr John W Frew

  25. Psychological complications of Stevens Johnson syndrome and toxic epidermal necrolysis

    Article • January 2024, International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)

    Dr John W Frew

  26. Global consensus process to establish a core data set for hidradenitis suppurativa registries

    Article • British Journal of Dermatology, November 2023, Oxford University Press (OUP)

    Dr John W Frew, Professor Gregor B Jemec

  27. Human dermal fibroblast subpopulations and epithelial mesenchymal transition signals in hidradenitis suppurativa tunnels are normalized by spleen tyrosine kinase antagonism in vivo

    Article • PLOS One, November 2023, PLOS

    Dr John W Frew

  28. The Serum Proteome of Pyoderma Gangrenosum is More Expansive Than That of Hidradenitis Suppurativa

    Article • Journal of the European Academy of Dermatology and Venereology, November 2023, Wiley

    Dr John W Frew

  29. Alterations to the Hidradenitis Suppurativa Serum Proteome with Spleen Tyrosine Kinase Antagonism: Proteomic Results from a Phase 2 Clinical Trial

    Article • Journal of Investigative Dermatology, October 2023, Elsevier

    Dr John W Frew

  30. Clinical reports: the overarching home for case series and case reports in the BJD

    Article • British Journal of Dermatology, August 2023, Oxford University Press (OUP)

    Dr John W Frew

  31. Resident cutaneous memory T-cells: A clinical review of their role in chronic inflammatory dermatoses and potential as therapeutic targets

    Article • British Journal of Dermatology, August 2023, Oxford University Press (OUP)

    Dr John W Frew

  32. Rapid Attenuation of B-Cell and IFN-γ–Associated Chemokines in Clinical Responders to Jak Inhibition with Upadacitinib in Hidradenitis Suppurativa

    Article • Journal of Investigative Dermatology, August 2023, Elsevier

    Dr John W Frew

  33. Mast cells are upregulated in hidradenitis suppurativa tissue, associated with epithelialized tunnels and normalized by spleen tyrosine kinase antagonism

    Article • Experimental Dermatology, July 2023, Wiley

    Dr John W Frew

  34. Maintenance of response to dupilumab in prurigo nodularis: A retrospective cohort study

    Article • JAAD International, June 2023, Elsevier

    Dr John W Frew

  35. Obesity and Hidradenitis Suppurativa: Targeting meta-inflammation for therapeutic gain?

    Article • Clinical and Experimental Dermatology, May 2023, Oxford University Press (OUP)

    Dr John W Frew

  36. Mast cells are upregulated in Hidradenitis Suppurativa Tissue, associated with epithelialized tunnels and normalised by Spleen Tyrosine Kinase Antagonism

    Article • April 2023, Cold Spring Harbor Laboratory Press

    Dr John W Frew

  37. Academic dermatology in Australia and New Zealand between 2017 and 2022: A cross‐sectional bibliometric analysis

    Article • Australasian Journal of Dermatology, March 2023, Wiley

    Dr John W Frew

  38. Baseline clinical, hormonal and molecular markers associated with clinical response to IL ‐23 antagonism in hidradenitis suppurativa: A prospective cohort study

    Article • Experimental Dermatology, March 2023, Wiley

    Dr John W Frew

  39. The Impact of Psoriasis Biologic Therapy Upon HIV Viral Load and CD4+ cell counts in HIV Positive Individuals: A Real‐World Cohort Study

    Article • Journal of the European Academy of Dermatology and Venereology, March 2023, Wiley

    Dr John W Frew

  40. Monkeypox: Cutaneous clues to clinical diagnosis

    Article • Journal of the American Academy of Dermatology, March 2023, Elsevier

    Dr John W Frew

  41. Baseline Clinical, Hormonal and Molecular Markers Associated with Clinical Response to IL-23 Antagonism in Hidradenitis Suppurativa: A Prospective Cohort Study

    Article • February 2023, Cold Spring Harbor Laboratory Press

    Dr John W Frew

  42. Human Dermal Fibroblast Subpopulations and Epithelial Mesenchymal Transition Signals in Hidradenitis Suppurativa Tunnels are Normalized by Spleen Tyrosine Kinase Antagonism in Vivo

    Article • February 2023, Cold Spring Harbor Laboratory Press

    Dr John W Frew

  43. In Search of Therapeutic Biomarkers to IL-23 Antagonism in Hidradenitis Suppurativa

    Article • British Journal of Dermatology, February 2023, Oxford University Press (OUP)

    Dr John W Frew

  44. Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study

    Article • Journal of the American Academy of Dermatology, February 2023, Elsevier

    Dr John W Frew

  45. Dupilumab-associated head and neck dermatitis resolves temporarily with itraconazole therapy and rapidly with transition to upadacitinib, with Malassezia-specific immunoglobulin E levels mirroring clinical response

    Article • Journal of the American Academy of Dermatology, January 2023, Elsevier

    Dr John W Frew

  46. Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study

    Article • Journal of the American Academy of Dermatology, December 2022, Elsevier

    Dr John W Frew

  47. Strongyloides screening prior to dupilumab therapy in atopic dermatitis: a retrospective cohort study evaluating screening utility

    Article • British Journal of Dermatology, October 2022, Oxford University Press (OUP)

    Dr John W Frew

  48. The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study

    Article • British Journal of Dermatology, October 2022, Oxford University Press (OUP)

    Dr John W Frew

  49. Adalimumab therapy is associated with increased faecal short chain fatty acids in hidradenitis suppurativa

    Article • Experimental Dermatology, August 2022, Wiley

    Dr John W Frew

  50. ACE2 Expression is Elevated in Tissue of Hidradenitis Suppurativa and Pyoderma Gangrenousm and Demonstrates a Different Pattern of Expression to Psoriasis Vulgaris

    Article • Journal of the European Academy of Dermatology and Venereology, August 2022, Wiley

    Dr John W Frew

  51. Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?

    Article • Clinical and Experimental Dermatology, August 2022, Oxford University Press (OUP)

    Dr John W Frew

  52. Interpretation of comorbidity risk in hidradenitis suppurativa: comparing odds ratio and ‘number needed to be exposed’

    Article • Journal of the European Academy of Dermatology and Venereology, July 2022, Wiley

    Dr John W Frew

  53. Interleukin‐17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum

    Article • British Journal of Dermatology, June 2022, Wiley

    Dr John W Frew

  54. A case series of early biologic therapy in guttate psoriasis: Targeting resident memory T cell activity as a potential novel therapeutic modality

    Article • JAAD Case Reports, June 2022, Elsevier

    Dr John W Frew

  55. Extramammary Paget’s disease: Harbinger of internal malignancy

    Article • Australian Journal of General Practice, May 2022, The Royal Australian College of General Practitioners

    Dr John W Frew

  56. Dupilumab‐associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia ‐specific IgE : a multicentre, prospective cohort study

    Article • British Journal of Dermatology, April 2022, Wiley

    Dr John W Frew

  57. Amplicon sequencing demonstrates comparable follicular mycobiomes in patients with hidradenitis suppurativa compared with healthy controls

    Article • Journal of the European Academy of Dermatology and Venereology, March 2022, Wiley

    Dr John W Frew, Professor Gregor B Jemec

  58. Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa

    Article • JAMA Dermatology, March 2022, American Medical Association (AMA)

    Dr John W Frew

  59. Pyoderma gangrenosum: A systematic review of the molecular characteristics of disease

    Article • Experimental Dermatology, February 2022, Wiley

    Dr John W Frew

  60. The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris

    Article • Journal of the American Academy of Dermatology, February 2022, Elsevier

    Dr John W Frew

  61. The pathogenesis of hidradenitis suppurativa: Evolving paradigms in a complex disease

    Article • Dermatological Reviews, January 2022, Wiley

    Dr John W Frew

  62. Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts

    Article • Skin Appendage Disorders, January 2022, Karger Publishers

    Dr John W Frew

  63. Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry

    Article • Journal of the American Academy of Dermatology, January 2022, Elsevier

    Dr John W Frew

  64. High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression

    Article • Journal of Allergy and Clinical Immunology, January 2022, Elsevier

    Dr John W Frew

  65. Antimicrobial peptides in hidradenitis suppurativa: a systematic review*

    Article • British Journal of Dermatology, November 2021, Oxford University Press (OUP)

    Dr John W Frew

  66. Large‐scale serum analysis identifies unique systemic biomarkers in psoriasis and hidradenitis suppurativa*

    Article • British Journal of Dermatology, October 2021, Oxford University Press (OUP)

    Dr John W Frew

  67. Autoantibody-Mediated Macrophage Responses Provide the Missing Link between Innate and Adaptive Immune Dysfunction in Hidradenitis Suppurativa

    Article • Journal of Investigative Dermatology, October 2021, Elsevier

    Dr John W Frew

  68. Clinical Considerations in the Management of Hidradenitis Suppurativa in Women:

    Article • International Journal of Women’s Dermatology, October 2021, Elsevier

    Dr John W Frew

  69. An Abscess Is Not a Descriptive Term but an Entity With a Universally Accepted Definition—A Clarification on Semantics—Reply

    Article • JAMA Dermatology, October 2021, American Medical Association (AMA)

    Dr John W Frew

  70. Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects

    Article • International Journal of Dermatology, September 2021, Wiley

    Dr John W Frew

  71. Rapid and sustained remission of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with IL-23p19 antagonist (risankizumab)

    Article • JAAD Case Reports, August 2021, Elsevier

    Dr John W Frew

  72. Assessing the Responsiveness of Sonographic Biomarkers to Brodalumab Therapy in Hidradenitis Suppurativa

    Article • Journal of the European Academy of Dermatology and Venereology, July 2021, Wiley

    Dr John W Frew

  73. Cellular Neurothekeoma

    Article • International Journal of Women’s Dermatology, July 2021, Elsevier

    Dr John W Frew

  74. The Impact of Body Mass Index Upon the Efficacy of Adalimumab in Hidradenitis Suppurativa

    Article • Frontiers in Medicine, June 2021, Frontiers

    Dr John W Frew

  75. Therapeutic biomarkers in hidradenitis suppurativa: one step closer to the clinic

    Article • British Journal of Dermatology, June 2021, Wiley

    Dr John W Frew

  76. Target molecules for future hidradenitis suppurativa treatment

    Article • Experimental Dermatology, June 2021, Wiley

    Dr John W Frew, Professor Gregor B Jemec

  77. Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa

    Article • Journal of Allergy and Clinical Immunology, June 2021, Elsevier

    Dr John W Frew

  78. Ultrasound‐guided de‐roofing of epithelialised tunnels of hidradenitis suppurativa

    Article • Australasian Journal of Dermatology, May 2021, Wiley

    Dr John W Frew

  79. Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed Glossary

    Article • JAMA Dermatology, April 2021, American Medical Association (AMA)

    Dr John W Frew, Professor Gregor B Jemec

  80. Cover Image

    Article • Experimental Dermatology, March 2021, Wiley

    Dr John W Frew

  81. In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes

    Article • Journal of Investigative Dermatology, March 2021, Elsevier

    Dr John W Frew

  82. Differential Profiles of Gamma‐Secretase‐Notch Signaling in Hidradenitis Suppurativa: The Need for Genotype‐Endotype‐Phenotype Analysis

    Article • British Journal of Dermatology, January 2021, Wiley

    Dr John W Frew

  83. Quantifying the natural variation in lesion counts over time in untreated hidradenitis suppurativa: Implications for outcome measures and trial design

    Article • JAAD International, December 2020, Elsevier

    Dr John W Frew

  84. The value of case reports in pharmacovigilance

    Article • British Journal of Dermatology, November 2020, Wiley

    Dr John W Frew

  85. Rapid resolution of pyoderma gangrenosum with brodalumab therapy

    Article • JAAD Case Reports, November 2020, Elsevier

    Dr John W Frew

  86. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study

    Article • Journal of the American Academy of Dermatology, November 2020, Elsevier

    Dr John W Frew

  87. The Erythema Q‐score, an Imaging Biomarker for Redness in Skin Inflammation

    Article • Experimental Dermatology, October 2020, Wiley

    Dr John W Frew

  88. What causes hidradenitis suppurativa ? – 15 years after

    Article • Experimental Dermatology, October 2020, Wiley

    Dr John W Frew, Professor Gregor B Jemec

  89. Dermal Tunnels Influence Time to Clinical Response and Family History Influences Time to Loss of Clinical Response in Hidradenitis Suppurativa Patients Treated with Adalimumab

    Article • Clinical and Experimental Dermatology, September 2020, Wiley

    Dr John W Frew

  90. A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance

    Article • Journal of Investigative Dermatology, September 2020, Elsevier

    Dr John W Frew

  91. Weekly Administration of Brodalumab in Hidradenitis Suppurativa: An Open Label Cohort Study

    Article • British Journal of Dermatology, August 2020, Wiley

    Dr John W Frew

  92. Global Hidradenitis Suppurativa COVID‐19 Registry: a registry to inform data‐driven management practices

    Article • British Journal of Dermatology, August 2020, Oxford University Press (OUP)

    Dr John W Frew

  93. Anti–Saccharomyces cervisiae antibodies in hidradenitis suppurativa: More than a gut feeling

    Article • Journal of Allergy and Clinical Immunology, August 2020, Elsevier

    Dr John W Frew

  94. Primary imputation methods impact efficacy results in hidradenitis suppurativa clinical trials

    Article • Journal of the American Academy of Dermatology, August 2020, Elsevier

    Dr John W Frew

  95. A Systematic Review andCritical Appraisal of Metagenomic and Culture Studies in Hidradenitis Suppurativa

    Article • Experimental Dermatology, July 2020, Wiley

    Dr John W Frew

  96. Ex Vivo Models and Interpretation of Mechanistic Studies in Hidradenitis Suppurativa

    Article • Journal of Investigative Dermatology, July 2020, Elsevier

    Dr John W Frew

  97. Hidradenitis suppurativa is an autoinflammatory keratinization disease: A review of the clinical, histologic, and molecular evidence

    Article • JAAD International, July 2020, Elsevier

    Dr John W Frew

  98. Doppler Ultrasound‐Based Non‐Invasive Biomarkers in Hidradenitis Suppurativa: Evaluation of Analytical and Clinical Validity

    Article • British Journal of Dermatology, June 2020, Wiley

    Dr John W Frew

  99. The Importance of Methodological Rigor in Proof-of-Concept Clinical Trials: A Lesson from Hidradenitis Suppurativa

    Article • Journal of Investigative Dermatology, June 2020, Elsevier

    Dr John W Frew

  100. Malignancy and infection risk during adalimumab therapy in hidradenitis suppurativa

    Article • Clinical and Experimental Dermatology, May 2020, Wiley

    Dr John W Frew

  101. The Asia Pacific Hidradenitis Suppurativa (APHiS) foundation: promoting hidradenitis suppurativa research in the Asia Pacific

    Article • International Journal of Dermatology, May 2020, Wiley

    Dr John W Frew

  102. COVID-19 and immunomodulator/immunosuppressant use in dermatology

    Article • Journal of the American Academy of Dermatology, May 2020, Elsevier

    Dr John W Frew

  103. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data

    Article • Journal of the American Academy of Dermatology, May 2020, Elsevier

    Dr John W Frew

  104. Beyond antibodies: B cells in Hidradenitis Suppurativa: Bystanders, contributors or therapeutic targets?

    Article • Experimental Dermatology, March 2020, Wiley

    Dr John W Frew

  105. Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa

    Article • British Journal of Dermatology, December 2019, Wiley

    Dr John W Frew

  106. Integrating complement into the molecular pathogenesis of Hidradenitis Suppurativa

    Article • Experimental Dermatology, November 2019, Wiley

    Dr John W Frew

  107. No evidence that impaired Notch signalling differentiates hidradenitis suppurativa from other inflammatory skin diseases

    Article • British Journal of Dermatology, November 2019, Wiley

    Dr John W Frew

  108. A Scoping Review of Non-invasive Imaging Modalities in Dermatological Disease: Potential Novel Biomarkers in Hidradenitis Suppurativa

    Article • Frontiers in Medicine, November 2019, Frontiers

    Dr John W Frew

  109. Prevalence of inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS): systematic review and adjusted meta‐analysis

    Article • International Journal of Dermatology, October 2019, Wiley

    Dr John W Frew

  110. Consensus definitions of disease activity in hidradenitis suppurativa: crossing the semantic gap

    Article • British Journal of Dermatology, October 2019, Wiley

    Dr John W Frew

  111. Epidermolizis bülloza yaşam kalitesi puanlarının klinik uygulamalarının geliştirilmesi: QOLEB anketinde klinik olarak anlamlı sonuçların tanımlanması

    Article • Mucosa, September 2019, Mucosa

    Dr John W Frew

  112. In silico Analysis of Gamma-Secretase-Complex Mutations in Hidradenitis Suppurativa Demonstrates Disease-Specific Substrate Recognition and Cleavage Alterations

    Article • Frontiers in Medicine, September 2019, Frontiers

    Dr John W Frew

  113. Putting nodule counts behind us: hidradenitis suppurativa outcome measures independent of descriptive semantics

    Article • British Journal of Dermatology, September 2019, Wiley

    Dr John W Frew

  114. Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies

    Article • British Journal of Dermatology, August 2019, Wiley

    Dr John W Frew

  115. Specimen Collection for Translational Studies in Hidradenitis Suppurativa

    Article • Scientific Reports, August 2019, Springer Science + Business Media

    Dr John W Frew

  116. Into the (gluteal) fold: pilonidal disease and hidradenitis suppurativa – association or continuum?

    Article • British Journal of Dermatology, August 2019, Wiley

    Dr John W Frew

  117. Contribution of fibroblasts to tunnel formation and inflammation in hidradenitis suppurativa/ acne inversa

    Article • Experimental Dermatology, July 2019, Wiley

    Dr John W Frew

  118. A systematic review and critical evaluation of immunohistochemical associations in hidradenitis suppurativa

    Article • F1000Research, June 2019, Faculty of 1000, Ltd.

    Dr John W Frew

  119. A systematic review of reported cases of pachyonychia congenita tarda

    Article • Clinical and Experimental Dermatology, May 2019, Wiley

    Dr John W Frew

  120. Lack of photographic documentation undermines assessment of hidradenitis suppurativa phenotypes: reply from the author

    Article • British Journal of Dermatology, April 2019, Wiley

    Dr John W Frew

  121. Inter‐rater reliability of phenotypes and exploratory genotype–phenotype analysis in inherited hidradenitis suppurativa

    Article • British Journal of Dermatology, April 2019, Wiley

    Dr John W Frew

  122. The contradictory inefficacy of methotrexate in hidradenitis suppurativa: a need to revise pathogenesis or acknowledge disease heterogeneity?

    Article • Journal of Dermatological Treatment, April 2019, Taylor & Francis

    Dr John W Frew

  123. Assessing the efficacy of new biologic therapies in hidradenitis suppurativa: consistency vs. bias in outcome measures in moderate and severe disease

    Article • Journal of the European Academy of Dermatology and Venereology, April 2019, Wiley

    Dr John W Frew

  124. Hidradenitis suppurativa and diabetes: big data bias masks a true association

    Article • Clinical and Experimental Dermatology, March 2019, Wiley

    Dr John W Frew

  125. The Hygiene Hypothesis, Old Friends, and New Genes

    Article • Frontiers in Immunology, March 2019, Frontiers

    Dr John W Frew

  126. Commentary: Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model

    Article • Frontiers in Immunology, February 2019, Frontiers

    Dr John W Frew

  127. Cutaneous neonatal Langerhans cell histiocytosis: a systematic review of case reports

    Article • F1000Research, January 2019, Faculty of 1000, Ltd.

    Dr John W Frew

  128. Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms

    Article • Therapeutic Advances in Chronic Disease, January 2019, SAGE Publications

    Dr John W Frew

  129. Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017

    Article • Experimental Dermatology, January 2019, Wiley

    Dr John W Frew

  130. A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa

    Article • F1000Research, December 2018, Faculty of 1000, Ltd.

    Dr John W Frew

  131. A systematic review and critical evaluation of immunohistochemical associations in hidradenitis suppurativa

    Article • F1000Research, December 2018, Faculty of 1000, Ltd.

    Dr John W Frew

  132. Complement, Hidradenitis Suppurativa and Pathogen-Driven Positive Selection

    Article • British Journal of Dermatology, November 2018, Wiley

    Dr John W Frew

  133. We Need to Talk About Notch:Notch Dysregulation as an Epiphenomenon in Inflammatory Skin Disease

    Article • British Journal of Dermatology, November 2018, Wiley

    Dr John W Frew

  134. A Retrospective Cohort Study of Melanoma Prevalence Stratified by Body Site in a Regional Australian Population 1994-2017: Site-Specific Protective Mechanisms

    Article • Photodermatology Photoimmunology & Photomedicine, November 2018, Wiley

    Dr John W Frew

  135. New therapeutics for itch in dermatomyositis

    Article • British Journal of Dermatology, September 2018, Wiley

    Dr John W Frew

  136. Secukinumab in pityriasis rubra pilaris: A case series demonstrating variable response and the need for minimal clinical datasets

    Article • JAAD Case Reports, June 2018, Elsevier

    Dr John W Frew

  137. Quality-of-Life Measures in Hidradenitis Suppurativa: The Importance of High-Quality Methodology and Standards

    Article • Journal of Cutaneous Medicine and Surgery, May 2018, SAGE Publications

    Dr John W Frew

  138. BJD research letters: concise, thought provoking and of general interest

    Article • British Journal of Dermatology, February 2018, Wiley

    Dr John W Frew

  139. Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 1

    Article • Australasian Journal of Dermatology, January 2018, Wiley

    Dr John W Frew

  140. Drug-associated hidradenitis suppurativa: A systematic review of case reports

    Article • Journal of the American Academy of Dermatology, January 2018, Elsevier

    Dr John W Frew

  141. Pharmaceutical Benefits Scheme listing of adalimumab for hidradenitis suppurativa: Is hidradenitis suppurativa a life-changing drug or does lifestyle change the drug?

    Article • Australasian Journal of Dermatology, December 2017, Wiley

    Dr John W Frew

  142. HLA-B*1502 haplotype screening prior to carbamazepine administration in individuals of south-east Asian ancestry nears cost-effectiveness in preventing severe cutaneous adverse drug reactions

    Article • Australasian Journal of Dermatology, December 2017, Wiley

    Dr John W Frew, Emma Kim

  143. Disease-specific health related quality of life patient reported outcome measures in Genodermatoses: a systematic review and critical evaluation

    Article • Orphanet Journal of Rare Diseases, December 2017, Springer Science + Business Media

    Dr John W Frew

  144. A systematic review and critical evaluation of reported pathogenic sequence variants in hidradenitis suppurativa

    Article • British Journal of Dermatology, September 2017, Wiley

    Dr John W Frew

  145. Lichen amyloidosis involving the scalp

    Article • Australasian Journal of Dermatology, July 2017, Wiley

    Dr John W Frew

  146. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration

    Article • Australasian Journal of Dermatology, May 2017, Wiley

    Dr John W Frew, Assocoiate Professor Marius Rademaker

  147. Highly Resistant Acrodermatitis Continua of Hallopeau and Pustular Psoriasis

    Article • Skin Appendage Disorders, January 2017, Karger Publishers

    Dr John W Frew

  148. Beyond the tip of the iceberg: the role of phosphoinositide 3-kinase/AKT in acne inversa/hidradenitis suppurativa

    Article • British Journal of Dermatology, March 2016, Wiley

    Dr John W Frew

  149. The early bird and the worm: a case of cercarial dermatitis

    Article • The Medical Journal of Australia, February 2016, Australasian Medical Publishing Co. Pty Ltd. (AMPCo)

    Dr John W Frew

  150. Adopting the orphan: The importance of recognising hidradenitis suppurativa as a systemic auto-inflammatory disease

    Article • Australasian Journal of Dermatology, January 2016, Wiley

    Dr John W Frew

  151. Tattoo-associated mycobacterial infections: an emerging public health issue

    Article • The Medical Journal of Australia, September 2015, Australasian Medical Publishing Co. Pty Ltd. (AMPCo)

    Dr John W Frew

  152. Fifty shades of yellow: a review of the xanthodermatoses

    Article • International Journal of Dermatology, July 2015, Wiley

    Dr John W Frew, Dedee Murrell, Dr Richard M Haber

  153. Adalimumab-induced porokeratosis

    Article • Australasian Journal of Dermatology, July 2015, Wiley

    Dr John W Frew

  154. Chlorophyll‐induced pseudoporphyria with ongoing photosensitivity after cessation – a case series of four patients

    Article • Journal of the European Academy of Dermatology and Venereology, April 2015, Wiley

    Dr John W Frew

  155. Phenotypic heterogeneity implies heterogeneous pathogenic pathways in hidradenitis suppurativa

    Article • Experimental Dermatology, March 2015, Wiley

    Dr John W Frew

  156. Multinucleate Cell Angiohistiocytoma

    Article • American Journal of Dermatopathology, March 2015, Wolters Kluwer Health

    Dr John W Frew

  157. Autoimmune Blistering Diseases and Corticosteroid Use: A Review of the Evidence

    Article • January 2015, Springer Science + Business Media

    Dr John W Frew

  158. Cyclophosphamide in Autoimmune Blistering Diseases: Safety, Efficacy and Evidence Base

    Article • January 2015, Springer Science + Business Media

    Dr John W Frew

  159. Living with Epidermolysis Bullosa: Reviewing the Impact on Individuals’ Quality of Life

    Article • January 2015, Springer Science + Business Media

    Dr John W Frew

  160. The clinical significance of drug interactions between dermatological and psychoactive medications

    Article • Dermatologic Therapy, January 2014, Wiley

    Dr John W Frew

  161. Health-related Quality of Life in Epidermolysis Bullosa: Validation of the Dutch QOLEB Questionnaire and Assessment in the Dutch Population

    Article • Acta Dermato-Venereologica, January 2014, Acta Dermato-Venereologica

    Dr John W Frew

  162. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa

    Article • Journal of the American Academy of Dermatology, December 2013, Elsevier

    Dr John W Frew

  163. The development and validation of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease

    Article • British Journal of Dermatology, October 2013, Wiley

    Dr John W Frew

  164. Measuring quality of life in epidermolysis bullosa in Mexico: Cross-cultural validation of the Hispanic version of the Quality of Life in Epidermolysis Bullosa questionnaire

    Article • Journal of the American Academy of Dermatology, October 2013, Elsevier

    Dr John W Frew

  165. Development of a Quality-of-Life Instrument for Autoimmune Bullous Disease

    Article • JAMA Dermatology, October 2013, American Medical Association (AMA)

    Dr John W Frew

  166. Diffuse melanosis cutis: A systematic review of the literature

    Article • Journal of the American Academy of Dermatology, March 2013, Elsevier

    Dr John W Frew

  167. Corticosteroid Use in Autoimmune Blistering Diseases

    Article • Immunology and Allergy Clinics of North America, May 2012, Elsevier

    Dr John W Frew

  168. Quality-of-Life Measurement in Blistering Diseases

    Article • Dermatologic Clinics, April 2012, Elsevier

    Dr John W Frew

  169. Corticosteroid Use in Autoimmune Blistering Diseases

    Article • Dermatologic Clinics, October 2011, Elsevier

    Dr John W Frew

  170. Evidence-Based Treatments in Pemphigus Vulgaris and Pemphigus Foliaceus

    Article • Dermatologic Clinics, October 2011, Elsevier

    Dr John W Frew

  171. Current Management Strategies in Paraneoplastic Pemphigus (Paraneoplastic Autoimmune Multiorgan Syndrome)

    Article • Dermatologic Clinics, October 2011, Elsevier

    Dr John W Frew

  172. Paraneoplastic Pemphigus (Paraneoplastic Autoimmune Multiorgan Syndrome): Clinical Presentations and Pathogenesis

    Article • Dermatologic Clinics, July 2011, Elsevier

    Dr John W Frew

  173. No Evidence That Human Papillomavirus Is Responsible for the Aggressive Nature of Recessive Dystrophic Epidermolysis Bullosa–Associated Squamous Cell Carcinoma

    Article • Journal of Investigative Dermatology, December 2010, Elsevier

    Dr John W Frew

  174. Autosomal dominant bullous dermolysis of the newborn associated with a heterozygous missense mutation p.G1673R in type VII collagen

    Article • Australasian Journal of Dermatology, August 2010, Wiley

    Dr John W Frew

  175. Categorizing immunofluorescence mapping in epidermolysis bullosa with pyloric atresia: Use as a broad prognostic indicator

    Article • Australasian Journal of Dermatology, June 2010, Wiley

    Dr John W Frew

  176. Erratum

    Article • British Journal of Dermatology, March 2010, Wiley

    Dr John W Frew

  177. Quality of Life Measurements in Epidermolysis Bullosa: Tools for Clinical Research and Patient Care

    Article • Dermatologic Clinics, January 2010, Elsevier

    Dr John W Frew

  178. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument

    Article • British Journal of Dermatology, December 2009, Wiley

    Dr John W Frew

  179. Performing surgery with a single electron: electrosurgery and quantum mechanics

    Article • Australian and New Zealand Journal of Surgery, October 2009, Wiley

    Dr John W Frew

  180. A ski and adventure camp for young patients with severe forms of epidermolysis bullosa

    Article • Journal of the American Academy of Dermatology, September 2009, Elsevier

    Dr John W Frew